文献速递艾滋病与性传播感染

人乳头瘤病毒检测即治与细胞学筛查预防人免疫缺陷病毒感染女性宫颈癌的随机临床试验:艾滋病临床试验组方案A5282

A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282.
PubMed 文献 · Clin Infect Dis · 2022-01-01

这项随机、开放标签、2期跨国临床试验纳入288名感染人免疫缺陷病毒且宫颈高危人乳头瘤病毒阳性的女性,比较立即冷冻治疗(A组)与细胞学筛查(B组)对活检证实的重度鳞状上皮内病变(bHSIL)结局的影响。随访至30个月,两组发生bHSIL的时间相似(P=.94),第6个月高危人乳头瘤病毒患病率亦相似(61% vs 70%,P=.13)。结论认为人乳头瘤病毒检测即治策略并未改善bHSIL结局,筛查即治项目需要更有效的治疗选择。

要点

  • A组27%入组时即有bHSIL,B组62%细胞学异常、15%诊断为bHSIL、8%接受LEEP。
  • 随访中A组21%、B组22%发生bHSIL,两组发生时间相似(P=.94)。
  • 第6个月高危人乳头瘤病毒患病率A组61% vs B组70%(P=.13)。

核心结论

  • 与细胞学筛查相比,人乳头瘤病毒检测即治策略未改善bHSIL结局,筛查即治项目需要更有效的治疗选择。

研究设计与样本

  • 随机、开放标签、2期跨国临床试验,纳入288名18岁及以上感染人免疫缺陷病毒且宫颈高危人乳头瘤病毒阳性、无宫颈病变或病变适合冷冻治疗的女性,随机分为立即冷冻治疗组(A组,145例)和细胞学筛查组(B组,143例),随访至30个月。

主要发现

  • A组145例中39例(27%)入组时存在bHSIL;B组143例中88例(62%)细胞学异常,22例(15%)诊断为bHSIL,12例(8%)接受LEEP。
  • 随访期间A组30例(21%)、B组31例(22%)发生bHSIL,两组发生bHSIL的时间相似(P=.94)。
  • 第6个月高危人乳头瘤病毒患病率A组61% vs B组70%(P=.13)。
  • 入组女性中位年龄35岁,84%接受抗逆转录病毒治疗,中位CD4计数501 cells/mm3。

临床怎么用

  • 原文结论未据此给出具体临床推荐,仅指出人乳头瘤病毒检测即治策略未改善bHSIL结局,筛查即治项目需要更有效的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytology-based cervical cancer screening followed by confirmation and treatment of biopsy-proven high-grade squamous intraepithelial lesions (bHSIL) is difficult to implement in resource-constrained settings. We hypothesized that high-risk human papillomavirus (hrHPV) testing followed by immediate cryotherapy of women with hrHPV (HPV screen-and-treat) may improve outcomes. METHODS: Randomized, open-label, phase 2, multinational clinical trial enrolling women with human immunodeficiency virus (HIV) age 18 or older with cervical hrHPV and having no cervical lesions or lesions appropriate for cryotherapy. Women were randomized to immediate cryotherapy (Arm A) or cytology-based screening (Arm B). For Arm A, cervical biopsies were obtained followed by cervical cryotherapy, and in Arm B, women with abnormal cytology underwent colposcopy followed by loop electroexcision procedure (LEEP) if bHSIL was detected. Women were followed through 30 months. The primary outcome was time to bHSIL detected from Month 6 through study completion. RESULTS: In total, 288 women (145 in Arm A, 143 in Arm B) were randomized: median age 35 years, 84% on antiretroviral therapy, median CD4 501 cells/mm3. In Arm A, 39 (27%) of women had bHSIL at entry, and in Arm B, 88 (62%) had abnormal cytology, 22 (15%) were diagnosed with bHSIL, 12 (8%) underwent LEEP. In follow-up, 30 (21%) and 31 (22%) developed bHSIL; time to bHSIL was similar between arms (P=.94). The prevalence of hrHPV at Month 6 was similar between arms (61% and 70%, P=.13). CONCLUSIONS: HPV test-and-treat was not associated with improved bHSIL outcomes as compared to cytology-based screening. More effective treatment options are required to improve outcomes from screen-and-treat programs. CLINICAL TRIALS REGISTRATION: NCT01315363.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wilkin T, Chen H, Sahasrabuddhe V, et al. A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282. Clin Infect Dis. 2022. PMID: 35294524. doi:10.1093/cid/ciac213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。